Renal Anemia – Landscape & Forecast – Disease Landscape & Forecast

Renal anemia is a common complication of chronic kidney disease (CKD). Although treatments—such as iron therapies, erythropoiesis-stimulating agents (ESAs), and HIF-PH inhibitors—are available, physicians, patients, and healthcare systems are concerned about their limitations. Agents of the novel HIF-PH inhibitor class, roxadustat and vadadustat, received a complete response letter (CRL) from the FDA (in August 2021 and March 2022, respectively) over safety concerns, despite being approved in Japan and Europe. In the United States, daprodustat has become the first HIF-PH inhibitor to launch for renal anemia patients who have been on dialysis. The U.S. launch of the second HIF-PH inhibitor, vadadustat, for the treatment of anemia due to CKD in adult patients on dialysis is expected during the study period. Although these new therapies offer advantages over current therapies, they will face major challenges, including reimbursement hurdles and an increasingly stringent regulatory environment.


  • What is the prevalence of renal anemia in the major pharmaceutical markets under study?
  • What opportunities do marketers of the emerging oral HIF-PH inhibitors have to promote their noninvasive route of administration, particularly for patients not on dialysis?
  • Will establishing cardiovascular (CV) safety be key for the market uptake of HIF-PH inhibitors, in view of the CV issues associated with current therapies?
  • With the imminent availability of biosimilars in the United States, how will emerging therapies that offer only incremental improvements over existing therapies fare?
  • How will the renal anemia therapy market evolve over the next 10 years?


  • Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
  • Primary research: 19 country-specific interviews with thought-leading nephrologists. Supported by survey data collected for this and other Clarivate research.
  • Epidemiology: Prevalence of renal anemia by country and diagnosed / drug-treated rates.
  • Emerging therapies: Coverage of select emerging therapies from preclinical to preregistration stages.
  • Market forecast features: 10-year, annualized, drug-level sales and patient share of key renal anemia therapies through 2032, segmented by brands / generics.


Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.


Disease Landscape & Forecast is updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.

Table of contents

launch Related Market Assessment Reports